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Summary
Background The incidence of epidermal keratinocyte-derived cutaneous squamous
cell carcinoma (cSCC) is increasing worldwide.
Objectives To study the role of the complement classical pathway components
C1q, C1r and C1s in the progression of cSCC.
Methods The mRNA levels of C1Q subunits and C1R and C1S in cSCC cell lines,
normal human epidermal keratinocytes, cSCC tumours in vivo and normal skin
were analysed with quantitative real-time polymerase chain reaction. The produc-
tion of C1r and C1s was determined with Western blotting. The expression of
C1r and C1s in tissue samples in vivo was analysed with immunohistochemistry
and further investigated in human cSCC xenografts by knocking down C1r and
C1s.
Results Significantly elevated C1R and C1S mRNA levels and production of C1r and
C1s were detected in cSCC cells, compared with normal human epidermal ker-
atinocytes. The mRNA levels of C1R and C1S were markedly elevated in cSCC
tumours in vivo compared with normal skin. Abundant expression of C1r and C1s
by tumour cells was detected in invasive sporadic cSCCs and recessive dystrophic
epidermolysis bullosa-associated cSCCs, whereas the expression of C1r and C1s
was lower in cSCC in situ, actinic keratosis and normal skin. Knockdown of C1r
and C1s expression in cSCC cells inhibited activation of extracellular signal-related
kinase 1/2 and Akt, promoted apoptosis of cSCC cells and significantly sup-
pressed growth and vascularization of human cSCC xenograft tumours in vivo.
Conclusions These results provide evidence for the role of tumour-cell-derived C1r
and C1s in the progression of cSCC and identify them as biomarkers and putative
therapeutic targets in cSCC.
What’s already known about this topic?
• The incidences of actinic keratosis, cutaneous squamous cell carcinoma (cSCC)
in situ and invasive cSCC are increasing globally.
• Few specific biomarkers for progression of cSCC have been identified, and no bio-
logical markers are in clinical use to predict the aggressiveness of actinic keratosis,
cSCC in situ and invasive cSCC.
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What does this study add?
• Our results provide novel evidence for the role of complement classical pathway
components C1r and C1s in the progression of cSCC.
What is the translational message?
• Our results identify complement classical pathway components C1r and C1s as
biomarkers and putative therapeutic targets in cSCC.
Keratinocyte-derived cutaneous squamous cell carcinoma
(cSCC) causes 20% of all skin-cancer-related deaths, with an
estimated 5-year metastasis rate of 5%.1–4 Currently, the inci-
dence of cSCC is increasing globally.5 The progression of cSCC
takes place from actinic keratosis (AK) to cSCC in situ (cSCCIS)
and eventually to invasive and metastatic cSCC. The main risk
factors for cSCC include long-term exposure to ultraviolet (UV)
radiation from sunlight, immunosuppression and chronic der-
mal ulcers.6 Moreover, chronic inflammation has been recog-
nized as an important factor in the development of cSCC.7
The complement system connects innate and acquired
immunity and initiates the inflammatory responses in host
defence.8 The complement system is activated in a sequential
manner via three distinct pathways (classical, lectin and alterna-
tive pathways), which converge in cleavage of the central com-
ponent C3 to C3a and C3b fragments. Covalent binding of C3b
to target cells promotes phagocytosis and initiates activation of
the terminal lytic pathway and formation of the membrane
attack complex.9 In addition, activation of the complement sys-
tem generates an inflammatory response and stimulates macro-
phage and B-cell activities. The small cleavage products C3a and
C5a of the main complement components C3 and C5 function
as anaphylatoxins by increasing vascular permeability and pro-
moting contraction of smooth muscle cells.10
The classical pathway of complement is typically activated
by binding of C1 complex to antibodies bound to their target
antigens. The C1 complex consists of six subcomponents of
C1q, each with a collagenous triple helix of subunits C1qA,
C1qB and C1qC and two copies each of the C1r and C1s sub-
units.11 The binding of C1 complex to a target results in a
conformational change in C1q, which initiates a stepwise pro-
teolytic activation of serine proteinases C1r and C1s.12 The
activities of C1r and C1s can be inhibited by the serine pro-
teinase inhibitor C1INH. C1s then cleaves C4 to C4a and C4b
fragments, and C4-bound C2 to C2a and C2b. This leads to
generation of the C3 convertase C4bC2a, which activates C3
and initiates the lytic pathway.13 Recent observations on the
diversity of C1q ligands and C1s substrates suggest that C1 has
functions outside the complement system.14–20
Our previous studies have shown that the expression of
complement factor H and complement factor I, two regulators
of the alternative pathway, and two activating components
complement factor B and C3, are significantly upregulated in
tumour cells in cSCCs, and that complement factor I,
complement factor B and C3 promote growth of cSCC
in vivo.21–23 However, the role of the classical pathway of com-
plement in the progression of cSCC is not known. The results
of the present study show marked upregulation of the expres-
sion of C1r and C1s by cSCC cells in culture and by cSCC
tumour cells in vivo. Furthermore, our results show that knock-
down of C1r and C1s inhibits activation of the extracellular
signal-related kinase (ERK)1/2 and phosphoinositide 3-kinase
(PI3K) signalling pathways, promotes apoptosis of cSCC cells
and suppresses vascularization and growth of cSCC xenografts
in vivo. These results provide novel evidence for the role of C1r
and C1s in the progression of cSCC and identify them as
biomarkers and potential therapeutic targets in cSCC.
Materials and methods
Detailed information on the materials and methods is provided
in Appendix S1 (see Supporting Information).
Ethical issues
Collection of normal skin and cSCC tissues and the use of
archival tissue specimens were approved by the ethics com-
mittee of the Hospital District of Southwest Finland (4/2006).
The research was carried out according to the Declaration of
Helsinki. All studied patients gave informed and written per-
mission before surgery, and the study was carried out with
the authorization of Turku University Hospital (Turku, Fin-
land). All experiments with mice were carried out with the
permission of the State Provincial Office of Southern Finland,
according to institutional guidelines.
Cell cultures
Human cSCC cell lines (n = 8) were initiated from surgically
removed cSCCs.24 Five cSCC cell lines were derived from pri-
mary cSCCs: UT-SCC-12A, UT-SCC-91, UT-SCC-105, UT-SCC-
111 and UT-SCC-118. Three cSCC cell lines were from meta-
static cSCCs: UT-SCC-7, UT-SCC-59A and UT-SCC-115. These
cell lines were authenticated by short tandem repeat DNA pro-
filing.24 Primary normal human epidermal keratinocytes
(NHEKs) were obtained from PromoCell (Heidelberg, Ger-
many). NHEKs were cultured from normal skin of patients (n
= 11) who had undergone mammoplastic surgery at Turku
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University Hospital, Turku, Finland. Cell cultures were per-
formed as previously described.21–23
Tissue samples
Primary cSCC samples (n = 6) were obtained from surgically
removed tumours in Turku University Hospital.25 Normal
human skin samples (n = 10) were collected from the upper arm
of healthy volunteers and during mammoplasty operation in
Turku University Hospital. Human liver RNA was obtained from
Human MTC Panel I (Clontech, Mountain View, CA, U.S.A.).
Altogether 260 archival formalin-fixed paraffin-embedded tissue
samples from sporadic, UV-induced cSCC (n = 115; mean age 79
years, range 45–102), cSCCIS (Bowen disease; n = 63; mean age
79 years, range 59–95), AK (n = 61; mean age 78 years, range
58–95) and normal skin (n = 21) were obtained from the
archives of the Department of Pathology, Turku University
Hospital. In addition, recessive dystrophic epidermolysis bul-
losa-associated cSCC (RDEBSCC) tissue samples (n = 16; mean
age 33 years, range 12–56) were stained and analysed.26,27
Statistical analysis
SPSS software (IBM, Armonk, NY, U.S.A.) was used for statisti-
cal analysis to determine the significance of differences
between two sample groups. For quantitative real-time
Fig 1. Expression of C1r and C1s is upregulated in cutaneous squamous cell carcinoma (cSCC) cells. (a) C1R and C1S mRNA levels in normal
human epidermal keratinocytes (NHEKs; n = 10) and cSCC cell lines (n = 8) were determined by quantitative real-time polymerase chain reaction
(qRT-PCR). RNA from human liver was used as a positive control. (b) The levels of C1r and C1s in NHEKs and cSCC cell lines were determined
by Western blotting of conditioned media under nonreducing conditions (upper panel), with b-actin in cell lysates as a sample control. C1r and
C1s protein levels were quantitated densitometrically and corrected for b-actin levels, and the ratio of C1s to C1r was calculated. The levels of the
cleaved form of C1s in conditioned media of NHEKs and cSCC cell lines were determined by Western blotting under reducing conditions (lower
panel). (c) Levels of C1R and C1S mRNA in normal skin (n = 10) and cSCC (n = 6) samples were analysed by qRT-PCR. (d) Xenografts established
with human cSCC cells were stained for immunohistochemistry using C1r and C1s antibodies. Scale bar = 100 lm. Statistical analysis was
performed with Mann–Whitney two-way U-test. *P < 005, **P < 001, ***P < 0001.
© 2019 The Authors. British Journal of Dermatology
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polymerase chain reaction (qRT-PCR) and staining analyses for
Ki-67, CD34 and active caspase-3, a two-tailed Mann–Whitney
U-test was used. Student’s t-test was used to analyse differences
in xenograft tumour volume and assays of cell number, viabil-
ity, apoptosis and migration, and the v2-test was used for com-
parison of intensities of immunohistochemistry (IHC) staining.
Results
Increased expression of C1r and C1s in cutaneous
squamous cell carcinoma cells and tumours
The mRNA levels of C1R, C1S and C1Q subunits in cSCC cell
lines and NHEKs were determined by qRT-PCR (Table S1; see
Supporting Information). The mean expression levels of C1R
and C1S mRNAs were significantly higher in cSCC cell lines (n
= 8) than in NHEKs (n = 10) (Fig. 1a). The mRNA levels of
C1Q subunits C1QA and C1QB and C1QC variants 1 and 2 were
very low in cSCC cell lines (n = 8) and NHEKs (n = 7) com-
pared with those in liver (Fig. S1; see Supporting Informa-
tion). Marked levels of C1r (80 kDa) and C1s (76 kDa)
proteins were detected in conditioned media of cSCC cell lines
by Western blotting, whereas the production of both C1r and
C1s by NHEKs was very low (Fig. 1b, upper panel). No corre-
lation between C1r and C1s protein levels produced by cSCC
cells was detected (Fig. 1b, upper panel).
The cleaved form of C1s (B chain, 28 kDa) was detected in
conditioned media of cSCC cells under reducing conditions,
indicating C1r activity in these cells (Fig. 1b, lower panel). Ele-
vated C1R and C1S mRNA levels were also noted in cSCC
Fig 2. Expression of C1r by tumour cells in cutaneous squamous cell carcinoma (cSCC). (a–f) Sections of tissue microarray blocks containing
samples from ultraviolet-induced sporadic cSCC (n = 106), recessive dystrophic epidermolysis bullosa-associated cSCCs (RDEBSCC, n = 15), cSCC
in situ (cSCCIS, n = 61), premalignant lesions (actinic keratosis, AK, n = 61) and normal skin (n = 8) were stained with C1r antibody. Strong
cytoplasmic staining was detected in tumour cells in cSCC (a, b) and RDEBSCC (c). Staining for C1r was absent or weak in normal skin (d). In AK
(e) and cSCCIS (f) staining was weak. Scale bar = 100 lm. (g) C1r immunostaining was scored as negative (), weak (+), moderate (++) or
strong (+++) based on the specific staining intensity. **P < 001, ***P < 0001 by v2-test.
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tumour tissue (n = 6) compared with normal skin tissue sam-
ples (n = 10) (Fig. 1c). In addition, IHC showed tumour-cell-
specific expression of C1r and C1s in xenograft tumours estab-
lished with human metastatic cSCC cells (UT-SCC-7) in the skin
of severe combined immunodeficient (SCID) mice (Fig. 1d).
Expression of C1r and C1s by tumour cells in cutaneous
squamous cell carcinomas in vivo
The expression of C1r and C1s in cSCC tumour tissue in vivo
was examined by IHC in tissue microarrays containing tissue
samples from different stages of epidermal carcinogenesis,
namely sporadic UV-induced cSCC (n = 115), cSCCIS (n = 63),
premalignant precursor lesion (AK, n = 61) and normal skin (n
= 21). In addition, tissue samples from RDEBSCC, an aggres-
sive form of cSCC (n = 16), were included in the IHC analysis.
Notable tumour-cell-specific expression of C1r was
detected in cSCCs (Fig. 2a, b) and RDEBSCC samples
(Fig. 2c). In general, the staining intensity for C1r was
stronger in cSCC tissue sections than in cSCCIS, AK and nor-
mal skin tissue samples (Fig. 2d–f). The staining intensity
was scored negative (), weak (+), moderate (++) or strong
(+++). Semiquantitative analysis revealed mainly strong or
moderate staining in tissue sections in cSCC. Moreover, in
RDEBSCC sections the cytoplasmic staining of C1r was strong
or moderate. On the other hand, in the cSCCIS, AK and nor-
mal skin groups, the proportion of strong or moderate stain-
ing was significantly lower than in cSCC or RDEBSCC
samples (Fig. 2g).
Prominent expression of C1s was also detected in tumour
cells in cSCC tissue samples (Fig. 3a, b) and in RDEBSCC tis-
sue sections (Fig. 3c). Normal skin stained weakly for C1s
Fig 3. Expression of C1s by tumour cells in cutaneous squamous cell carcinoma (cSCC). (a–f) Sections of tissue microarray blocks containing
samples from ultraviolet-induced sporadic cSCC (n = 115), recessive dystrophic epidermolysis bullosa-associated cSCCs (RDEBSCC, n = 16), cSCC
in situ (cSCCIS, n = 63), premalignant lesions (actinic keratosis, AK, n = 57) and normal skin (n = 21) were stained with C1s antibody.
Cytoplasmic staining for C1s was moderate (a) or strong (b) in cSCC and strong in RDEBSCC (c). In normal skin the staining for C1s was mainly
weak (d). In AK (e) and cSCCIS (f) staining was weak or moderate. Scale bar = 100 lm. (g) C1s immunostaining was scored as negative (),
weak (+), moderate (++) or strong (+++) based on the specific staining intensity. *P < 005, ***P < 0001 by v2-test.
© 2019 The Authors. British Journal of Dermatology
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(Fig. 3d). In premalignant lesions (AK) (Fig. 3e) and in
cSCCIS (Fig. 3f) the proportion of strong or moderate staining
for C1s was significantly lower than in cSCC samples. Semi-
quantitative analysis revealed strong or moderate staining for
C1s in the majority of tissue sections in the cSCC and
RDEBSCC groups (Fig. 3g). In comparison, the proportion of
negative and weak staining for C1s was significantly higher in
AK and cSCCIS than in cSCC tissues. In normal skin the
expression of C1s was negative or weak in most tissue samples
(Fig. 3g).
Knockdown of C1r and C1s promotes apoptosis of
cutaneous squamous cell carcinoma cells
To elucidate the functional role of C1r and C1s in cSCC cells,
their expression was silenced by specific small interfering (si)
RNAs (Fig. 4a, b; and Figs S2–S4; see Supporting Informa-
tion). Knockdown of C1r (Fig. 4c; and Fig. S2c–g) and C1s
(Fig. 4d; and Fig S2a, c–g) resulted in a significant decrease
in the growth of cSCC cells. Knockdown of C1r or C1s had no
marked effect on the growth of NHEKs (Fig. S3; see Support-
ing Information). Additionally, significant reduction in the
viability of cSCC cells was noted 72 h after transfection with
C1r siRNAs (Fig. S4c) and C1s siRNAs (Fig. S4d).
An increased number of TUNEL-positive apoptotic cells was
detected 48 h after transfection with C1r (Fig. 4e, g; and
Fig. S5; see Supporting Information) and C1s siRNA (Fig. 4f,
g; and Fig. S5a, b, d) compared with cells transfected with
control siRNA. Similar results on cSCC cell viability (UT-SCC-
7, -12A, -59A, -91, -105, -111) and apoptosis (UT-SCC-7,
-12A, -91, -105, -111, -115) were obtained with six cSCC
cell lines. The migration rate of cSCC cells in a scratch wound
model was significantly reduced after knockdown of C1r
(Fig. 5a, b) and C1s (Fig. 5c, d). Similar results on the migra-
tion rate of cSCC cells were obtained with two cSCC cell lines
(UT-SCC-7 and -12A). Knockdown of C1r and C1s upregu-
lated the production of matrix metalloproteinase (MMP)-9 in
cSCC cells (UT-SCC-7) (Fig. S6; see Supporting Information).
Knockdown of C1r and C1s suppresses growth of
cutaneous squamous cell carcinoma in vivo
The role of C1r and C1s on cSCC growth in vivo was examined
in a xenograft model. cSCC cells (UT-SCC-91) were
Fig 4. Knockdown of C1r and C1s promotes apoptosis of cutaneous squamous cell carcinoma (cSCC) cells. (a, b) cSCC cells (UT-SCC-12A) were
transfected with C1R small interfering (si)RNA (C1r siRNA_7 or C1r siRNA_11; 75 nmol L1) (a) or C1S siRNA (C1s siRNA_5; 120 nmol L1)
(b) and control siRNA. Cell lysates were analysed by Western blotting 8 days after transfections. The levels of C1R and C1S were quantitated
densitometrically and corrected for b-actin levels in the same samples. (c, d) cSCC cells (UT-SCC-12A) were transfected with control siRNA, C1R
(75 nmol L1) (c) or C1S siRNAs (120 nmol L1) (d). The confluency of the cells was determined at the indicated time points using IncuCyte
ZOOM (n = 6–8; mean  SEM). (e–g) UT-SCC-12A cells were transfected with C1R (75 nmol L1) or C1S (120 nmol L1) siRNAs or control
siRNA; 48 h after transfection apoptotic cells were detected with TUNEL staining, and the relative number of TUNEL-positive cells was counted
(mean  SEM) (g). Representative images after C1r (e) and C1s (f) knockdown are shown. Scale bar = 1 lm. *P < 0.05, **P < 0.01, ***P <
0.001 by t-test
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transfected with C1R, C1S or control siRNA, incubated for 72
h and injected (7 9 106 cells) subcutaneously into the back
of SCID mice. The growth of cSCC xenograft tumours with
C1r or C1s knockdown was significantly reduced compared
with control siRNA tumours (Fig. 6a). Histological analysis of
xenografts harvested 16 days after implantation showed that
the C1r and C1s knockdown tumours contained less tumour
tissue than the control tumours (Fig. 6b). Furthermore, the
relative number of proliferating Ki-67-positive cells (Fig. 6b, c)
and the density of CD34-positive blood vessels were signifi-
cantly lower in C1r and C1s knockdown tumours (Fig. 6b, d).
On the other hand, the percentage of active caspase-3-positive
apoptotic cells was significantly higher in C1r and C1s knock-
down tumours than in control tumours (Fig. 6b, e).
Alteration of the gene expression profile in cutaneous
squamous cell carcinoma cells after C1s knockdown
To gain mechanistic insight into the functional role of C1r
and C1s in cSCC progression, C1s expression was knocked
down in three cSCC cell lines and gene expression profiling
was performed by mRNA sequencing. Ingenuity Pathway
Analysis revealed significant downregulation of metastasis-
related biofunctions after C1s knockdown (Fig. 7a).
Furthermore, the genes significantly regulated following C1s
knockdown were associated with gene ontology terms related
to signalling pathways regulating cell proliferation [negative regu-
lation of MAP kinase activity MAPK cascade and negative regulation of
MAPK kinase activity] and cell viability (Phosphatidylinositol 3-kinase
activity and phosphatidylinositol-4,5-bisphosphate 3-kinase activity)
(Fig. 7). Expression of several dual-specificity phosphatases
was significantly upregulated in gene ontology term negative reg-
ulation of MAPK cascade (Fig. 8a). Additionally, gene ontology
term Phosphatidylinositol 3-kinase activity contained significantly
downregulated genes including PIK3R3, which codes for PI3K
regulatory subunit 3 and PIK3IP1, which codes for phos-
phatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit b,
which positively regulate the PI3K signalling pathway
(Fig. 8b). Analysis of cell lysates by Western blotting after C1s
knockdown showed that the levels of phosphorylated Akt and
phosphorylated ERK1/2 were decreased, indicating inhibition
in the activation of the PI3K and ERK1/2 signalling pathways,
respectively (Fig. 9).
Discussion
The complement system plays an important role in innate
immunity and is activated via three distinct pathways
Fig 5. Knockdown of C1r and C1s inhibits migration of cutaneous squamous cell carcinoma (cSCC) cells. UT-SCC-12A cells were transfected with
C1R (75 nmol L1) (a) or C1S (120 nmol L1) (c) small interfering (si)RNAs or control siRNA, and incubated for 48 h (n = 8) (mean  SEM). A
wound was made using 96-well WoundMaker and incubation was continued in 05 mmol L1 hydroxycarbamide. Representative images after C1r
(b) and C1s (d) knockdown are shown. Scale bar = 300 lm. *P < 005, **P < 001, ***P < 0001 by t-test.
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(classical, lectin and alternative), all of which lead to lytic
pathway activation and target cell lysis. In the classical path-
way, the first component (the C1qr2s2 complex) is activated
by at least two surface-bound Fc regions of antigen-bound
IgMs or IgGs. The tertiary structure of C1q is first altered
resulting in autoactivation of serine proteinase C1r, which
then activates C1s, also a serine proteinase.12 The activation of
the classical pathway can also be initiated in an antibody-inde-
pendent manner by binding of C1q to other ligands, including
C-reactive protein,28 serum amyloid P component29 and
Fig 6. Knockdown of C1r and C1s suppresses growth of cutaneous squamous cell carcinoma (cSCC) in vivo. (a) cSCC cells (UT-SCC-91) were
transfected with C1R small interfering (si)RNA_5 (n = 7), C1S siRNA_5 (n = 8) (120 nmol L1) or control siRNA (n = 8) and incubated for 72 h.
Cells (7 9 106) were injected subcutaneously into the back of severe combined immunodeficient mice and the size of tumours was measured
twice a week (mean  SEM). (b) Xenografts were harvested after 16 days and stained with haematoxylin and eosin (HE), and for
immunohistochemistry for the proliferation marker Ki-67, the vascular endothelial marker CD34 and the apoptotic marker active caspase-3, with
Mayer’s haematoxylin as counterstain. Representative stainings from each group are shown. Arrows indicate CD34-positive blood vessels. Scale bar
= 100 lm. (c–e) The percentage of Ki-67-positive cells (c), the number of CD34-positive blood vessels (d) and the percentage of active caspase-
3-positive cells (e) were counted. *P < 005, **P < 001, ***P < 0001 by Mann–Whitney U-test.
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membrane blebs of apoptotic cells.30 Recently, the role of
complement in cancer progression has gained attention.31–35
It has been shown that tumour-cell-derived complement com-
ponents can promote cancer growth in an autocrine manner.36
In addition, a high expression level of complement compo-
nent C3 in primary tumour was recently shown to correlate
with the rate of metastasis across the blood–brain barrier.37
Recent observations show that locally produced C1q can act
as a cancer-promoting factor in the tumour microenvironment
independently of complement activation.38 Our results show
that the mRNAs for C1q subunits are not expressed by cSCC
cells. In addition, our previous studies showed that cSCC cells
do not express mRNAs for the C4 or C2 components of the
classical pathway.21,22 However, the results of the present
study show that cSCC cell-derived C1s is specifically cleaved
and activated in culture in the absence of C1q. Therefore, the
data presented in this study suggest that C1r and C1s
contribute to cSCC tumour progression independently of com-
plement classical pathway activation and can act without C1q,
C4 or C2.
It is possible that C1r is activated autocatalytically in the
absence of C1q and subsequently activates C1s in the tumour
microenvironment of cSCC. However, several types of cells
produce C1q subunits, such as macrophages,38 bone-marrow-
derived cells39 and dermal microvascular endothelial cells in
wounds.40 It is therefore also possible that C1q derived from
stromal cells or circulation is present in the cSCC tumour
microenvironment, allowing assembly of the C1 complex. In
our experiments, C1r and C1s were secreted to the medium
of cSCC cells in culture, indicating the extracellular function
of C1r and C1s in the tumour microenvironment. Interest-
ingly, knockdown of C1s resulted in significant downregula-
tion of biofunctions related to metastasis in cSCC cells. As a
serine proteinase, C1s has been shown to activate latent MMP-
Fig 7. Alteration of the gene expression profile in cutaneous squamous cell carcinoma (cSCC) cells after C1s knockdown. cSCC cell lines (UT-SCC-
12A, -59A and -91) were transfected with C1S small interfering (si)RNA_5 or control siRNA (120 nmol L1) and mRNA sequencing was
performed 72 h after transfection. Summary of Ingenuity Pathway Analysis biofunctions, gene ontology (GO) terms, Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathways and Reactome related to C1s knockdown (P < 005, fold change log2 10).
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9,41 suggesting a putative mechanism for C1s in promoting
cancer growth, angiogenesis and metastasis. Recently, knock-
down of MMP-9 has been shown to increase migration and
invasion of oral SCC cells.42 Accordingly, increased expression
of MMP-9 was noted in cSCC cells after knockdown of C1r
and C1s, suggesting that the stimulatory effect of C1r and C1s
on cSCC cell migration may involve MMP-9.
Our results also show that silencing the expression of C1r
or C1s in cSCC cells in culture resulted in significant reduction
in cell viability and promoted apoptosis of cSCC cells. These
findings are in accordance with the results of our studies in a
xenograft model in SCID mice showing suppression of tumour
growth and vascularization and an increased number of apop-
totic cells in vivo following knockdown of C1r or C1s in cSCC
cells. Together these observations provide evidence for the
important roles of C1r and C1s in cSCC tumour growth in vivo.
As C1s is proteolytically activated by C1r and serves as the
effector of C1r we studied the mechanistic role of C1r and
C1s in cSCC progression by RNA-sequencing-based gene
expression profiling after knockdown of C1s expression in
three distinct cSCC cell lines. Interestingly, several gene ontol-
ogy terms related to cell viability and proliferation were sig-
nificantly regulated in cSCC cells following knockdown of
C1s, and this was associated with inhibition of the activity of
the PI3K and ERK1/2 signalling pathways. In accordance with
our results, complement activation along the vasculature of
the tumours has been shown to be associated with the growth
and increased angiogenesis of tumours.43–45 Activation of the
classical pathway has previously been reported in papillary
thyroid carcinoma,46 in lung cancer44 and in a mouse model
of cervical cancer.47 Moreover, deposition of classical pathway
components has been detected in oral and oropharyngeal
SCCs,48 follicular and mucosa-associated lymphoid tissue lym-
phomas49 and astrocytomas.50 These results are in accordance
with those of the present study and provide additional evi-
dence for the role of the classical pathway of complement in
cancer progression.
Solar UV radiation, chronic inflammation and immunosup-
pression are important risk factors for development of cSCC.
In recent studies, the role of the complement system in
tumour growth by altering the host immune response and
promoting chronic inflammation has been emphasized.51–53
Complement activation leads to the formation of anaphylatox-
ins C3a, C4a and C5a, which may alter the tumour microenvi-
ronment by attracting macrophages, increasing histamine
release from mast cells and increasing vascular permeability.54
It has also been shown that C1s can cleave and inactivate the
alarmin high-mobility group box 1, and this may regulate
inflammation by suppressing lipopolysaccharide-induced pro-
duction of proinflammatory cytokines by monocytes, macro-
phages and dendritic cells.20
The complement system is a complex network of effectors,
receptors and regulators, some of which exert functions
beyond complement activation. Complement components
serve as important effectors of monoclonal antibodies used in
cancer therapy, and therefore it is important to identify the
expression and function of distinct complement components
in different types of cancers. Recently, the efficacy of immune
Fig 8. Alteration of the gene expression profile in cutaneous squamous cell carcinoma (cSCC) cells after C1s knockdown. (a) Significantly
regulated genes belonging to the gene ontology term ‘negative regulation of MAPK cascade’ are shown in gene blot. (b) Significantly regulated genes
belonging to the gene ontology term ‘phosphatidylinositol 3-kinase activity’ are shown in gene blot.
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checkpoint inhibitor therapy in advanced and metastatic cSCC
has been demonstrated.55 In this respect it is interesting that
anaphylatoxin C5a has been shown to promote tumour pro-
gression, and that blocking complement receptor C5a results
in decreased expression of the immune checkpoint molecule
programmed death ligand 1 in a murine lung cancer model.52
In addition to markers for personalized cancer therapy, com-
plement components can serve as diagnostic and prognostic
biomarkers in cancer. Combinations of complement compo-
nents could serve as biomarkers for predicting the aggressive-
ness of cSCC for different patients, as demonstrated by
detection of different complement components by a multiplex
detection array to predict progression of oral SCC.56
In summary, the results of the present study show tumour-
cell-specific overexpression of complement system compo-
nents C1r and C1s in cSCC cells in vivo. Furthermore, the
results demonstrate that C1r and C1s promote the growth of
cSCC xenografts in vivo by enhancing tumour vascularization
and tumour cell viability. These results provide evidence for
important roles for C1r and C1s in cSCC progression and sug-
gest them as tumour-cell-derived molecular markers in cSCC.
The feasibility of this approach in assessing disease progression
has recently been demonstrated in SCC.56 At present, a num-
ber of novel pharmacological inhibitors targeted against speci-
fic complement components are under development.57 It is
therefore of importance to elucidate the role of individual
complement components in the growth and development of
cSCC in order to identify targets for these new drugs in the
therapy of metastatic and unresectable advanced cSCC.
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